Biodexa Pharmaceuticals (BDRX) Other Non-Current Assets (2018)
Biodexa Pharmaceuticals (BDRX) posted Other Non-Current Assets of $12.0 million for Q4 2018, down 34.75% sequentially from $18.4 million in Q2 2018.
Biodexa Pharmaceuticals (BDRX) Other Non-Current Assets (2018) Analysis & Trends
Biodexa Pharmaceuticals has reported Other Non-Current Assets for 1 years, with the latest figure at $12.0 million in Q4 2018.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $12.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $12.0 million (changed N/A YoY) and the FY2018 annual result came in at $12.5 million, changed N/A from the prior year.
- Other Non-Current Assets declined to $12.0 million in Q4 2018 per BDRX's latest filing, from $18.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $18.4 million in Q2 2018 and troughed at $12.0 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 12.03 Mn |
| Jun 30, 2018 | 18.44 Mn |